biotechNew

Recursion Pharmaceuticals

AI-native biotech mapping biology at industrial scale.

weight 0.0PaidLaunched 2026-06-07

💸 No earnings reported yet

What it is

The largest AI-native biotech by headcount, combining automated wet-lab experiments with machine learning across one of the sector's broadest drug pipelines following its Exscientia merger.

How AI plugs in

Machine-learning models trained on petabytes of in-house automated-lab cell imagery map phenotypes to compounds, letting the platform predict drug effects across a vast chemical space.